Dysfunctional Uterine Bleeding

Dysfunctional uterine bleeding

Contents of the post

  • Overview
  • Types of dysfunctional uterine bleeding
  • Diagnosis
  • Treatment
  • References and Further reading

Overview

Dysfunctional uterine bleeding is abnormal bleeding resulting from changes in the normal hormonal control of the menstruation.

  • Dysfunctional uterine bleeding occurs most commonly at the beginning and end of reproductive years.
  • 20% of the cases occur in adolescent girls and more than 50% occur in women older than 45.
  • Dysfunctional uterine bleeding commonly results when the level of estrogen remains high.
  • High levels of estrogen are not balanced by appropriate levels of progesterone and release of the egg does not occur.
  • As a result, the lining of the uterus thickens.
  • This condition is called endometrial hyperplasia.
  • The lining is then shed incompletely and irregularly, which causes bleeding.
  • Bleeding is irregular, prolonged and sometimes heavy.
  • This type of bleeding is common in women who have the polycystic ovarian syndrome.

Types of Dysfunctional uterine bleeding

  • This type of dysfunctional uterine bleeding occurs in 10% of the women who are ovulating.
  • In this type, since estrogen levels are low, progesterone secretion is prolonged.
    • Because of this, the uterine lining is shredded irregularly and break-through bleeding occurs.
  • Some studies related this type of dysfunctional uterine bleeding with fragile blood vessels in the uterus.
  • In about 90% of the patients, Dysfunctional Uterine Bleeding occurs when a woman is not ovulating.
  • A varying degree of the interval between 2 menstruation and the absence of ovulation and a luteal phase are the characteristic features of anovulatory bleeding or menstruation.
    • This is considered as infertility since there is an absence of ovulation.
    • This is more common in women in their premenopause age or in early puberty.
    • It may also occur in teenagers due to a delay in the maturation of the reproductive system.
    • In this case, women will not develop a mature egg and release it.
    • As a result of which, corpus luteum which produces progesterone is not formed; leading to a continuous production of estrogen. This causes an overgrowth of the uterine lining.
    • When this happens, the menstruation is delayed. Also, the menstrual bleeding, when it occurs is prolonged and heavy.
  • The exact mechanism of the occurrence of dysfunctional uterine bleeding is unknown.

Causes

  • Menorrhagia
    • In this condition, menstrual periods are characterized by excessively heavy bleeding.
    • This may happen due to endocrine dysfunction.
  • Metrorrhagia
    • In this condition, menstrual bleeding occurs unexpectedly between the next expected menstruation and the previous periods.
    • Just like menorrhagia, this may also happen due to endocrine dysfunction.
  • A decrease in estrogen levels.
    • This may lead to mid-cycle bleeding.
  • Surface lesions of the genital tract
  • A decrease in the levels of progesterone.
    • This may lead to late-cycle bleeding.
  • Endometriosis
    • In this condition, uterine lining (known as endometrium) grows outside the uterus; for example on the ovaries.
    • This usually leads to heavy bleeding during regular periods.
  • Polycystic Ovarian Syndrome
  • Uterine polyps
    • Polyps are small growths occurring in the uterus.
    • The cause of uterine polyps is unknown.
    • This causes spotting between the periods.
  • Uterine fibroids
    • Just like polyps, fibroids are also the small growths affecting the uterus or the uterine lining or the uterine muscles.
    • The causes of uterine fibroids are unknown.
  • Sexually Transmitted Diseases
    • In this condition, bleeding occurs after the intercourse.
  • Psychological stress
  • Obesity
    • This is a medical condition in which excessive fat gets accumulated in the body leading to detrimental effects on health.
  • Anorexia
    • This is also known as Anorexia nervosa.
    • It is an eating disorder in which a patient has a strong desire to remain thin and an intense fear of gaining weight. As a result, the patient restricts the amount of food intake.
  • Exercise
  • Rapid weight loss
  • Rapid weight gain
  • Endocrinopathy
    • This is a term commonly used for the diseases of the endocrine gland.
    • Some of the endocrine disorders are listed below:
      • Adrenal insufficiency
      • Diabetes
      • Cushing’s disease
      • Hyperthyroidism
      • Hypothyroidism
      • Gigantism and other problems related to growth hormone
      • Hypopituitarism
      • Multiple Endocrine Neoplasia (Type I and II)
      • Precocious puberty
      • Polycystic Ovarian Syndrome
  • Neoplasms
  • Surface lesions of the genital tract
  • Medicines
  • Unknown causes

Symptoms

  • Unexpected and heavy menstrual bleeding
  • Other symptoms may accompany depending upon the underlying cause.

Diagnosis

Evaluation of physical signs and symptoms

  • Calculation of BMI to determine whether the patient is obese or not.
  • Symptoms of androgen excess
    • Hirsutism
    • Acne
  • Symptoms of a bleeding disorder
    • Purpura – Formation of red or purple colored spots on the skin.
    • Ecchymosis – This is discoloration of the skin due to an underneath internal bleeding.
  • Signs of anemia

Other tests

  • Dysfunctional uterine bleeding is diagnosed when all other possible causes of vaginal bleeding have been excluded.
  • The first step towards the diagnosis of Dysfunctional uterine bleeding is a thorough evaluation of medical history followed by physical evaluation.
  • Ruling out of diseases or pathological conditions which causes;
    • Epistaxis
    • Bleeding gums
    • Easy bruising
    • The occurrence of excessive bleeding during childbirth
  • Bleeding due to hormonal replacement therapy, other hormonal treatments, and hormonal contraception should be ruled out.
  • Other iatrogenic causes of bleeding should also be ruled out.
  • Confirm the presence or absence of bleeding disorders.
  • The results of a blood test can help doctors estimate the extent of the blood loss.
  • Laboratory assessment of following parameters should be done.
    • Hemoglobin
    • CBC (Complete Blood Count)
    • Human Chorionic Gonadotropin
    • LH or Luteinizing hormone
    • FSH Follicle Stimulating Hormone
    • Prolactin
    • TSH (Thyroid Stimulating Hormone)
    • T3
    • T4
    • Complete androgen profile
      • Testosterone
      • Dehydroepiandrosterone (DHEA) – This hormone is produced in the adrenal cortex.
      • Androstenedione (A4) –  This hormone is produced by the testes and the ovaries.
      • Androstenediol (A5) – This hormone is an intermediate in the synthesis of testosterone from DHEA within the body.
      • Androsterone
      • Dihydrotestosterone (DHT) – This hormone is a metabolite of testosterone. Since it binds more strongly to androgen receptors, it is a more potent androgen than testosterone.
    • Coagulation factors and disorders
      • Factor XI
      • Von Willebrand disease
      • Primary thrombocytopenia
      • Secondary thrombocytopenia
  • PAP smear
  • Transvaginal sonography may be used to determine whether the uterine lining is thickened.
  • A sonography scan will also confirm the presence or absence of the formation of uterine fibroids and uterine polyps.
  • An ultrasound scan will also help to find out the cause of an internal bleeding if any.
  • If the risk of the cancer of the uterine lining is high, an endometrial biopsy is performed before drug treatment is started.
  • Endometrial biopsy is done if one or more of the following conditions are confirmed;
    • The growth of uterine polyps
    • The growth of uterine fibroids
    • Thickening of the uterine lining
  • If the cells in the uterine lining have undergone abnormal changes, a biopsy will reveal whether such changes are due to hormonal imbalance or a tumor.
  • Women at risk include those who are 35 years or older, those who are substantially overweight and those who have the polycystic ovarian syndrome, high blood pressure or diabetes.

Treatment

  • Treatment of a woman suffering from dysfunctional uterine bleeding should be approached with 4 basic goals:
    • To stop the current bleeding.
    • Treat the underlying pathological condition if any.
    • To prevent future bleeding.
    • To avoid anemia by replacing the lost iron.
  • Treatment depends on the woman’s age, how heavy the bleeding is whether the uterine lining is thickened and whether the woman wishes to become pregnant.
  • When the uterine lining is thickened but its cells are normal, hormones may be used.
  • Women who have heavy bleeding may be treated with oral contraceptives containing estrogen and progestin.
  • When bleeding is very heavy, estrogen may be given intravenously until the bleeding stops.
  • Sometimes progestin is given by mouth at the same time or started 2 or 3 days later.
  • Bleeding usually stops in 12 to 24 hours.
  • Low doses of oral contraceptives may be prescribed for at least 3 months.
  • Treatment given with oral contraceptives or intravenous estrogen may be inappropriate for some women like postmenopausal women or women with significant risk factors for heart or blood vessel disease.
  • These women may be given progestin alone by mouth for 10 to 14 days each month.
  • For women, who wish to become pregnant, clomiphene may be given by mouth.
  • Desmopressin should be employed in patients with coagulation disorders.
  • If the uterine lining remains thickened or bleeding persists despite the treatment with hormones, dilation and curettage is usually needed.
  • In this procedure, tissue from the uterine lining is removed by scraping.
  • When the uterine lining is thickened and contains abnormal cells, particularly in women who are older than 35 years and women who don’t want to become pregnant, treatment begins with a high dose of progestin.
  • If the cells continue to be abnormal after treatment, a hysterectomy is performed, because the abnormal cells may become cancerous.

Complications resulting from dysfunctional uterine bleeding

  • Anemia is a major complication arising due to dysfunctional uterine bleeding.
  • This is because, in dysfunctional uterine bleeding or DUB, heavy bleeding occurs; which may lead to blood loss and anemia.
  • This condition is usually treated by recommending the patient to use an iron supplement and eat more fruits and leafy vegetables.
  • In certain extreme cases of severe blood loss, blood transfusion should also be considered.

Click here to go to Women’s health issues forums.

Click here to read more.

Bravender T, Emans SJ (June 1999). “Menstrual disorders. Dysfunctional uterine bleeding”. Pediatr. Clin. North Am. 46 (3): 545–53, viii. PMID 10384806.

“Dysfunctional Uterine Bleeding”. Retrieved 2010-01-23.

Bourdrez P, Bongers MY, Mol BW (July 2004). “Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy”. Fertil. Steril. 82 (1): 160–6, quiz 265. doi:10.1016/j.fertnstert.2003.12.025. PMID 15237006.

ACOG Committee on Practice Bulletins—Gynecology. American College of Obstetricians and Gynecologists. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet. 2001;72(3):263–271.

Albers JR, Hull SJ, Wesley RM. Abnormal uterine bleeding. Am Fam Physician. 2004;69:1916-1926.

Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A. Treatment of menorrhagia. Am Fam Physician. 2007;75(12):1813–1819.

Ash SJ, Farrell SA, Flowerdew G: Endometrial biopsy in DUB. J Reprod Med 1996 Dec; 41(12): 892-6.

Astrup K, Olivarius Nde F. Frequency of spontaneously occurring postmenopausal bleeding in the general population. Acta Obstet Gynecol Scand. 2004;83:203-207.

Athanatos D, Pados G, Venetis CA, et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double-blind, randomized controlled trial. Clin Exp Obstet Gynecol. 2015. 42 (3):347-51.

Beaumont H, Augood C, Duckitt K, et al. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev.2002;(2):CD001017.-

Beers MH, Berkow R. eds. Dysfunctional uterine bleeding, In: The Merck Manual. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:1941-1942.

Behera MA, Price TM. Dysfunctional uterine bleeding. eMedicine. 2010 .

Bennett AR, Gray SH. What to do when she’s bleeding through: the recognition, evaluation, and management of abnormal uterine bleeding in adolescents. Curr Opin Pediatr. 2014 Aug. 26 (4):413-9.

Bradley LD, Widrich T. State-of-the-art flexible hysteroscopy for office gynecologic evaluation. J Am Assoc Gynecol Laparosc. 1995;2:263-267.

Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11(3):293–307.

Chullapram T, Song JY, Fraser IS: Medium-term follow-up of women with menorrhagia treated by rollerball endometrial ablation. Obstet Gynecol 1996 Jul; 88(1): 71-6.

Claessens EA, Cowell CA: Dysfunctional uterine bleeding in the adolescent. Pediatr Clin North Am 1981 May; 28(2): 369-78.

Committee on Practice Bulletins—Gynecology. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013 Jul. 122 (1):176-85.

Crosignani PG, Rubin B: Dysfunctional uterine bleeding. Hum Reprod 1990 Jul; 5(5): – Rubin B.

Deligeoroglou EK, Creatsas GK. Dysfunctional uterine bleeding as an early sign of polycystic ovary syndrome during adolescence. Minerva Ginecol. 2015 Aug. 67 (4):375-81.

DeVore GR, Owens O, Kase N: Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding–a double-blind randomized control study. Obstet Gynecol 1982 Mar; 59(3): 285-91.

DeVore GR, Owens O, Kase N: Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding–a double-blind randomized control study. Obstet Gynecol 1982 Mar; 59(3): 285-91.

Diaz S, Croxatto HB, Pavez M: Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception 1990 Jul; 42(1): 97-109.

Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol. 2001;97:630-636.

Dodson MG: Use of transvaginal ultrasound in diagnosing the etiology of menometrorrhagia. J Reprod Med 1994 May; 39(5): 362-72.

Edlund M, Blomback M, von Schoultz B, et al. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol. 1996;53:234-238.

Edlund M, Blomback M, von Schoultz B: On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996 Dec; 53(4): 234-8.

Ehrmann DA. Polycystic ovary syndrome. N Engl J Med.2005;352:1223-1226.

Ely JW, Kennedy CM, Clark EC, Bowdler NC. Abnormal uterine bleeding: a management algorithm. J Am Board Fam Med. 2006;19(6):590–602.

Estephan A, Sinert RH. Dysfunctional uterine bleeding. eMedicine. 2010 .

Falcone T, Desjardins C, Bourque J: Dysfunctional uterine bleeding in adolescents. J Reprod Med 1994 Oct; 39(10): 761-4.

Ferenczy A, Gelfand M: The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989 Jan; 160(1): 126-31.

Ferenczy A, Gelfand MM, Tzipris F: The cytodynamics of endometrial hyperplasia and carcinoma. A review. Ann Pathol 1983 Sep; DA – 19831220(3): 189-201.

Franks S, Adams J, Mason H: Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol 1985 Sep; DA – 19860122(3): 605-32.

Guido RS, Stovall DW. Endometrial sampling procedures. UpToDate [online serial]. Waltham, MA: UpToDate; 2008.

Halberg L, Hogdahl AM, Nilsson L, et al. Menstrual blood loss-a population study. Acta Obstet Gynecol Scand.1966;45:320-351.

Hataska H. The evaluation of abnormal uterine bleeding. Clin Obstet Gynecol. 2005;48:258-273.

Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev. 2012 Sep 12. 9:CD001895.

Hill DA. Abnormal uterine bleeding: avoid the rush to hysterectomy. J Fam Pract. 2009;58(3):136–142.

Hill NC, Oppenheimer LW, Morton KE. The aetiology of vaginal bleeding in children. A 20-year review. Br J Obstet Gynaecol. 1989;96:467-470.

Hokenstad AN, El-Nashar SA, Khan Z, Hopkins MR, Famuyide AO. Endometrial ablation in women with abnormal uterine bleeding related to ovulatory dysfunction: a cohort study. J Minim Invasive Gynecol. 2015 Nov-Dec. 22 (7):1225-30.

Hopkins MP, Androff L, Benninghoff AS: Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol 1988 Nov; 159(5): 1121-2.

Jain S, Vaid NB, Narang Y, Suneja A, Guleria K. A Randomised Controlled Trial Comparing the Efficacy and Side-Effects of Intravaginal Ring (Nuvaring(®)) With Combined Oral Hormonal Preparation in Dysfunctional Uterine Bleeding. J Clin Diagn Res. 2016 Mar. 10 (3):QC21-4.

James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009 Jul. 201(1):12.e1-8.

Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011 Apr 21. 342:d2151.

Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998;351:485-489.

Kadir RA, Economides DL, Sabin CA: Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998 Feb 14; 351(9101): 485-9.

Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding. A Nordic multicenter study. Am J Obstet Gynecol. 1995;172:1488-1494.

Khrouf M, Terras K. Diagnosis and management of formerly called “dysfunctional uterine bleeding” according to PALM-COEIN FIGO classification and the new guidelines. J Obstet Gynaecol India. 2014 Dec. 64 (6):388-93.

Kouides PA. Evaluation of abnormal bleeding in women. Curr Hematol Rep. 2002;1:11-18.

Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(4):CD000249.-

Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev.2008;(1):CD001016.-

Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev.2000;(2):CD001016.-

Lobo RA. Abnormal uterine bleeding: ovulatory and anovulatory dysfunctional uterine bleeding, management of acute and chronic excessive bleeding. In: Comprehensive Gynecology. Vol. 5th. Philadelphia, PA: Mosby Elsevier; 2007:915–931.

Maness DL, Reddy A, Harraway-Smith CL, Mitchell G, Givens V. How best to manage dysfunctional uterine bleeding. J Fam Pract. 2010;59(8):449–458.

March CM: Hysteroscopy. J Reprod Med 1992 Apr; 37(4): 293-311; discussion 311-2.

Margolis MT, Thoen LD, Boike GM: Asymptomatic endometrial carcinoma after endometrial ablation. Int J Gynaecol Obstet 1995 Dec; 51(3): 255-8.

Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006;(2):CD003855.

Maslyanskaya S, Talib HJ, Northridge JL, Jacobs AM, Coble C, Coupey SM. Polycystic Ovary Syndrome: An Under-recognized Cause of Abnormal Uterine Bleeding in Adolescents Admitted to a Children’s Hospital. J Pediatr Adolesc Gynecol. 2017 Jun. 30 (3):349-355.

Mathew M, Gowri V, Rizvi SG. Saline infusion sonohysterography—an effective tool for evaluation of the endometrial cavity in women with abnormal uterine bleeding. Acta Obstet Gynecol Scand. 2010;89(1):140–142.

Medverd JR, Dubinsky TJ. Cost analysis model: US versus endometrial biopsy in evaluation of peri- and post-menopausal abnormal vaginal bleeding. Radiology.2002;222:619-627.

Meyer WR, Walsh BW, Grainger DA: Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstet Gynecol 1998 Jul; 92(1): 98-103.

Munster K, Schmidt L, Helm P. Length and variation in the menstrual cycle—a cross-sectional study from a Danish country. Br J Obstet Gynaecol. 1992;99:422-429.

Nagele F, O’Connor H, Davies A, et al. 2500 outpatient diagnostic hysteroscopies. Obstet Gynecol. 1996;88:87-92.

PDR: Physicians’ Desk Reference. 53rd ed. 1999.

Porter MRS, ed. Merck Manual (Online Medical Library). Merck Sharp & Dohme Corp.; 2009.

Ravn SH, Rosenberg J, Bostofte E: Postmenopausal hormone replacement therapy–clinical implications. Eur J Obstet Gynecol Reprod Biol 1994 Feb; 53(2): 81-93.

Rezk M, Masood A, Dawood R. Perimenopausal bleeding: Patterns, pathology, response to progestins and clinical outcome. J Obstet Gynaecol. 2015 Jul. 35 (5):517-21.

Roach L. Uterine Bleeding: ACOG Updates Guidelines. Medscape Medical News. Jun 21 2013. Available at http://www.medscape.com/viewarticle/806735. Accessed: July 10, 2013.

Rose EH, Aledort LM: Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991 Apr 1; drug effects(7): 563-8.

Rosenthal AN, Panoskaltsis T, Smith T, et al. The frequency of significant pathology in women attending a general gynaecological service for postcoital bleeding. BJOG.2001;108:103-106.

Schneider LG: Causes of abnormal vaginal bleeding in a Family Practice Center. J Fam Pract 1983 Feb; 16(2): 281-3.

Scott S. Abnormal bleeding in the pediatric patient. Postgrad Obstet Gynecol. 2006;26:1-5.

Serden SP. Diagnostic hysteroscopy to evaluate the cause of abnormal uterine bleeding. Obstet Gynecol Clin North Am.2000;27:277-286.

Shobeiri MJ, Atashkhoii S. The risk of menstrual abnormalities after tubal sterilization: a case control study. BMC Womens Health. 2005;5(1):5.

Shwayder JM. Pathophysiology of abnormal uterine bleeding. Obstet Gynecol Clin North Am. 2000;27:219-234.

Singh RH, Blumenthal P. Hormonal management of abnormal uterine bleeding. Clin Obstet Gynecol.2005;48:337-352.

Smith CB: Dysfunctional uterine bleeding. Am Fam Physician 1987 Sep; 36(3): 161-8.

Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998;280:1510-1517.

Speroff L, Glass R, Kase N: Dysfunctional Uterine Bleeding. In: Clinical Gynecologic Endocrinology & Infertility. 1999; 575-591.

Stewart A, Cummins C, Gold L, et al. The effectiveness of levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol. 2001;108:74-86.

Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal bleeding. Obstet Gynecol. 2002;99:663-670.

Teichmann A, Apter D, Emerich J, Greven K, Klasa-Mazurkiewicz D, Melis GB, et al. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception. 2009 Dec. 80(6):504-11.

van Bogaert LJ: Diagnostic aid of endometrium biopsy. Gynecol Obstet Invest 1979; 10(6): 289-97.

Vitagliano A, Bertin M, Conte L, et al. Thermal balloon ablation versus transcervical endometrial resection: evaluation of postoperative pelvic pain in women treated for dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 2014. 41(4):405-8.

Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004;190:1216-1223.

Wathen PI, Henderson MC, Witz CA: Abnormal uterine bleeding. Med Clin North Am 1995 Mar; 79(2): 329-44.

Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs.2003;63:1417-1433.

Wilansky DL, Greisman B: Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol 1989 Mar; 160(3): 673-7.

Wren BG. Dysfunctional uterine bleeding. Aust Fam Physician. 1998;27:371-377.

Wren BG: Dysfunctional uterine bleeding. Aust Fam Physician 1998 May; 27(5): 371-7.

By |2018-08-30T13:37:28+00:00December 24th, 2017|Disease/pathological condition|2 Comments

About the Author:

B. Pharm (K.L.E. society's S.V.V. Patil College of Pharmacy, Bengaluru) M. Pharm (Maharishi Arvind Institute of Pharmacy, Jaipur)

2 Comments

  1. Shalini February 13, 2018 at 5:52 pm - Reply

    Thanks for the information, Dhruv!

  2. pinoy tv April 14, 2018 at 6:05 pm - Reply

    Thanks for sharing this good information. I like is very much, please keep it up

Leave A Comment

WE NEED YOUR HELP IN CREATING AWARENESS ABOUT DISEASES AND MEDICINES

In today's fast paced life, we often come across minor health issues that we often neglect due to lack of time for paying a visit to a doctor, which usually takes away 2-3 hours of a person's time and are expensive too. Further more, such minor conditions may grow big at any time if neglected. Our aim in setting up this platform is that any person can search for any health condition or medicines and can get all the needed information within hardly 10-15 minutes, which saves a lot of time and money. After going through every information, if the person has any questions, he/she can go to our forums section and raise a topic. This will help him/her decide better whether he/she needs to pay an immediate visit to a doctor or can it wait for a day or two? Help us in bringing awareness about diseases and medicines by spreading the word to at least 5 of your friends and relatives.
Select your currency